PSI Opens New Italian Office

ZUG, Switzerland--Today, PSI CRO, a full-service contract research organization, announced opening of a new operational office in Italy. The Italian office further expands PSI's well-established presence in Europe and strengthens PSI's ability to deliver global clinical trials. The PSI CRO Italy S.r.l. office is located just outside Milan at Via Badia n.55, 20060 Gessate. It will give PSI the location and support to continue attracting and recruiting top talent in the industry.

PSI has been placing clinical trials in Italy for a number of years on behalf of pharmaceutical and biotech sponsors. They have gained extensive knowledge and experience with local investigative sites in the areas of oncology, haematology, haemophilia, acute care, infectious diseases, CNS, diabetes, and other therapeutic areas.

About PSI CRO AG: PSI is a privately held, full-service contract research organization (CRO), operating globally. PSI positions itself as a no-nonsense CRO capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI's global reach supports the operations of clinical trials across multiple countries and continents. PSI has exceptionally high repeat and referral business rates that are indicative of a commitment to be the best CRO in the world as measured by clients and employees. Global headquarters are located in Zug, Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.